Skip to content

Pain Perception in Suicidal Behavior Vulnerability

Pain Perception in Suicidal Behavior Vulnerability

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02915679
Acronym
DOCS
Enrollment
167
Registered
2016-09-27
Start date
2015-06-17
Completion date
2021-05-06
Last updated
2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Episode

Keywords

Suicidal behavior, psychological and social pain, physical pain, pain perception

Brief summary

In France, almost 1 death on 50 is a suicide. The suicide occurs in unbearable psychic pain where mental trouble has a major influence. It is classified as preventable mortality. According to interpersonal psychological theory of suicide, the repeated exposition to stressful and painful events (as physical abuse) would facilitate suicide attempt through the increased pain tolerance. The social pain (or psychical pain on the broader sense) and physical pain are closely linked. The investigators hypothesize that the measure of painful perception will be significantly superior on suicidals attempters compared to non-attempters. It will be the case for recent suicide attempters and former suicide attempters, suggesting a suicidal vulnerability trait. Moreover, the investigators expect that social distress induced by a social exclusion paradigm will be significantly superior on suicide attempters compared to non-attempters. The aim of the study is to investigate the physical and psychic pain on depressed subjects with or without history of suicide attempts. After a clinical evaluation (psychiatric symptomatology, personality trait, suicidal dimension), subjects will be submitted to a painful thermic stimulation and will participate at a computer test of social exclusion (named Cyberball).

Detailed description

242 depressed patients ( 81 recent suicide attempters, 81 former suicide attempters, 80 non-attempters) First visit : clinical assessment Second visit : pain evaluation and blood sample (from one day to a week maximum after the first visit).

Interventions

OTHERBlood sample for genetic purpose, psychiatric assessment and pain investigation

All the participant will performed the same evaluation and blood analysis: * A clinical assessment by psychiatrics assessing psychiatric disorder and suicidal behavior * Thermal stimulation for pain assessment * Computer game named Cyberball: test of social exclusion * Self report questionnaire for the assessment of reject sensitivity, relationship style, impulsivity, childhood trauma. * Routine blood sampling

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* aged by 18 years old * came from West Europe, excepted Basque and Sardinian (because of genetics analysis) * main diagnosis of major depressive episode (DSM V criteria) * not having take antalgics in the 24 hours before assessment * received a minimal psychotrope treatment (clinician evaluation) * Able to understand nature, aims, methodology of the study * Agree to cooperate in clinical and biological assessment * Having signed informed consent Specific inclusion criteria : 81 recent suicide attempters (being hospitalised for suicidal attempts and having realised a suicide attempts 8 days before inclusion) 81 former suicide attempters (having realised in his lifetime a suicide attempt, one month before inclusion)

Exclusion criteria

* Current diagnosis of manic, hypomanic or alcohol dependance or substance abuse in the last 6 months, or diagnosis of schizophrenia or schizoaffective disorder in his lifetime * Current algic and chronic neurologic disease * Current or actual treatment by tricyclic antidepressant and Serotonin and norepinephrine reuptake inhibitors(SNRIs) * Pregnancy * Patients on protective measure

Design outcomes

Primary

MeasureTime frameDescription
Pain tolerance reported by the patientDuring thermal stimulationtemperature measured when the subject will perceive as intolerable the pain following a painful stimulation performed using a thermode

Secondary

MeasureTime frameDescription
Pain threshold reported by the patientDuring thermal stimulationcomparison between the three groups of the pain threshold (temperature perceived as painful)
Temperature assessed at 4/10 on likert scaleDuring thermal stimulation performed at the inclusioncomparison between the three groups of the temperature assessed at 4/10 on a visual analogic painful scale, kinetics of pain intensity by visual analog scale (VAS) scale.
Kinetics of pain intensityDuring thermal stimulation performed at the inclusioncomparison between the three groups of kinetics of pain intensity by visual analog scale (VAS) scale.
Social distress perception assessed by social distress questionnaireAt V2 (one week maximum after the inclusion)comparison between the three groups of the score of social distress scale after cyberball game
Pain intensity reported by the patientDuring thermal stimulationcomparison between the three groups of the pain intensity (assessed by likert scale) at constant temperature (43 ° C)
Social rejection sensitivity assessed by the Rejection Sensitivity Questionnaire (RSQ)At the inclusioncomparison between the three groups of the score of social rejection sensitivity by RSQ
Psychological pain intensityAt V2 (one week maximum after the inclusion)comparison between the three groups of the score of psychological pain intensity assessed by VAS scale.
Measure of cardiac frequency in response to thermal painAt V2 (one week maximum after the inclusion)comparison between the three groups of the cardiac frequency.
Social distress perception assessed by the Rejection Sensitivity Questionnaire (RSQ)At the inclusioncomparison between the three groups of the score of social distress scale after cyberball game

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026